After Pfizer received the green signal for emergency use in the United Kingdom and Bahrain, its Indian unit has applied to the Drug Controller General of India (DCGI).In the application, Pfizer India has sought approval from DCGI for the import and distribution of the vaccine for sale.
Pfizer has developed the Corona virus vaccine in collaboration with BioNotech.
The company claims that this vaccine is 95 percent effective and completely safe against infection.
The company has first obtained approval for its emergency use in the United Kingdom (UK) and then in Bahrain.
Pfizer recently said that it would talk to the government to explore the possibilities of using its vaccine. In its application, the company has also sought exemption from distribution of vaccines in India as well as clinical trials here.Significantly, a foreign vaccine has to undergo clinical trials for use in India, but the company has cited new rules for exemption from this.
Sources say that Pfizer India applied for approval for emergency use on 4 December.
Pfizer’s vaccine needs to be stored at -70 degrees. India does not currently have this level of cold storage facility. In this case, Pfizer’s vaccine may face many challenges in India.
AIIMS Director Dr. Randeep Guleria has also expressed such concern.
He said that it would be challenging to deliver this vaccine in rural areas, for this it would be very difficult to make cold chains.
According to estimates, the cost of a vaccine dose in India can range from Rs 2,950 to Rs 3,700.